澳门·新莆京游戏大厅(官方)APP下载安装·Maigoo百科

About Sciarray

Professional and more focused

About us

 


Founded in 2001 and headquartered in Shenzhen China, Sciarray is a global provider of in vitro diagnostics (IVD) and instruments. We focus on the providing global medical diagnostics solutions. We have owned comprehensive diagnostic technologies: molecular diagnostic/Chemiluminescence (CLIA)/Biological chip/Rapid biochemical test/Gene methylation and medical devices.


Sciarray management team is consist of experienced and accomplished professionals, and their career experiences range from managing global research and product development projects in major international companies and institutions, hospital management, business development, marketing and sales for in vitro diagnostics. The venture backed company has devoted major efforts for developing the next generation diagnostic marker for immune mediated disease such as Systemic Lupus Erythematosus (SLE) and look for collaboration with international partners for global markets.


The clinic diagnostic on SLE is needed more accuracies in globe. The promoter low-methylation of Interferon-induced protein 44-like(IFI44L) gene is a new world-wide powerful marker for SLE clinic diagnostical. IFI44L promoter low-methylation is the only one high special and sensitive marker for SLE clinic diagnostics.


Corporate Culture

Corporate Mission

Corporate Mission

Innovative Life Technology For Serving Human Health

Corporate vision

Corporate vision

Innovation Pioneer of IVD Industry

Core values

Core values

Continuous innovation and pursuiting for excellence

Development philosophy

Development philosophy

Respection, achievement, trust, innovation, openness, professionalism

2022 Development
DEVELOP

2022

State Food and Drug Administration's innovative medical device products: systemic lupus erythematosus gene methylation detection reagent "Termine" is about to be launched! It will fill the gap of genetic diagnosis of systemic lupus erythematosus at home and abroad, and improve the diagnosis and treatment standards.

2021 Development
DEVELOP

2021

Microarray antinuclear antibody spectroscopy products (the only ones at home and abroad) and urinary iodine detection reagents have won the registration certificate and are officially on the market.

2020 Development
DEVELOP

2020

The Systemic Lupus Erythematosus Gene Methylation Marker Detection Kit was awarded the NMPA Special Approval for Innovative Medical Devices.

2018 Development
DEVELOP

2018

Antinuclear antibody profile, urinary iodine detection, allergen detection chip declaration and registration.

2017 Development
DEVELOP

2017

The microarray reader obtained the registration certificate and went on sale. Breakthroughs have been made in multiplex antibody detection products and methylation detection products for respiratory pathogens.

2016 Development
DEVELOP

2016

The automatic microarray reactor was successfully developed, and the diabetes chip and infertility chip were registered and sold, and won the 2016 Shenzhen Science and Technology Progress Award.

2015 Development
DEVELOP

2015

"Research and industrial application of key technologies of protein chips" won the second prize of Shenzhen Science and Technology Progress Award

2022

2021

2020

2018

2017

2016

2015

Tel

Tel
+86 (0)755-26623699
26625938

WeChat

XML 地图